نتائج البحث 251-260 من 23602 لعملية البحث عن B cell lymphomas
... cell lymphoma, Cutaneous b-cell lymph...oma, Diffuse large b-cell lymphoma, Follicular lymphoma, Small lymphocytic lymphoma, B-cell lymphoma, T-cell lymphoma.
... B-cell lymphoma 2 (BCL2) inhibitor. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel.
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), ...
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers. We ...
... B-cell lymphoma 2 (BCL2) inhibitor. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma.
Multiple myeloma, B-cell lymphoma, Non-Hodgkin lymphoma, T-cell lymphoma, Small lymphocytic lymphoma, Follicular lympho...ma, Hodgkin lymphoma. إظهار المزيد ...
... B-cell Lymphoma (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by ...
... B-cell lymphoma, Lymphoma, Amyloido...sis, T-cell lymphoma, Follicular lymphoma. إظهار المزيد من مجالات التخصص من أجل Yi Lin, M.D., Ph.D.
Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.